Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024

This report describes CDC’s recommendation that all people aged ≥65 years and people ages 6 months–64 years with moderate or severe immunocompromise receive a second 2024–2025 COVID-19 vaccine dose 6 months after their last dose.

Authors

Publication Details

Journal
MMWR Morbidity and Mortality Weekly Report
Published
2024-12-12
DOI
https://doi.org/10.15585/mmwr.mm7349a2
Citations
22
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
8.56

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024

Danielle Moulia, Oliver Brooks, Ruth Link‐Gelles, Katherine E. Fleming-Dutra et al.
22 citations
MMWR Morbidity and Mortality Weekly Report
SARS-CoV-2 and COVID-19 Research
8.56
article

Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024

Danielle Moulia, Oliver Brooks, Ruth Link‐Gelles, Katherine E. Fleming-Dutra, Georgina Peacock, Monica Godfrey, Lauren E. Roper, George A. Kuchel, H. Keipp Talbot, Lakshmi Panagiotakopoulos, Noel T. Brewer, Robert Schechter, Christopher A. Taylor
article en
22 citations

Abstract

This report describes CDC’s recommendation that all people aged ≥65 years and people ages 6 months–64 years with moderate or severe immunocompromise receive a second 2024–2025 COVID-19 vaccine dose 6 months after their last dose.

MMWR Morbidity and Mortality Weekly ReportVol. 73(49)
U.S. Department of Defense, Yale University, Council of State and Territorial Epidemiologists, Kaiser Permanente, Brown University, Children's Hospital of Philadelphia, Vanderbilt University, Memorial Sloan-Kettering Cancer Center, George Washington University, University of Washington, Johns Hopkins University, American Pharmacists Association, Public Health Agency of Canada, Marshfield Clinic Research Institute, Vanderbilt University Medical Center, Kaiser Permanente Washington Health Research Institute, Northwell Health, Public Health Agency, National Institutes of Health, Centers for Disease Control and Prevention, School of Medicine, Stanford University, University of California, Los Angeles, Biomedical Advanced Research and Development Authority, University of Colorado School of Medicine, Anschutz Medical Campus
Good health and well-being
Openalex Percentile: Top 1%
SARS-CoV-2 and COVID-19 Research
8.56
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.